Latest news with #MISSISSAUGA
Associated Press
6 days ago
- Health
- Associated Press
Imfinzi approved in Canada as first and only perioperative immunotherapy for muscle invasive bladder cancer
MISSISSAUGA, ON, Aug. 6, 2025 /CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Imfinzi® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant Imfinzi monotherapy treatment after radical cystectomy. The approval is based on results from the NIAGARA Phase III trial, which were published in The New England Journal of Medicine.1,2 In a planned interim analysis, the Imfinzi-based perioperative regimen demonstrated a statistically significant and clinically meaningful 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus neoadjuvant chemotherapy with radical cystectomy alone (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001). Estimated median EFS was not yet reached for the Imfinzi plus gemcitabine and cisplatin arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event free at two years compared to 59.8% in the comparator arm.2 Results from the key secondary endpoint of overall survival (OS) showed that the Imfinzi-based perioperative regimen reduced the risk of death by 25% versus the comparator arm (based on OS HR of 0.75; 95% CI 0.59-0.93; p=0.011). Median survival was not yet reached for either arm. An estimated 82.2% of patients treated with the regimen were alive at two years compared to 75.2% in the comparator arm.2 Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. The most common adverse events (any Grade, occurring in ≥10% of patients) for the Imfinzi plus chemotherapy arm were nausea (53.6%), fatigue (51.5%), neutropenia (40.4%), anemia (38.7%), constipation (38.7%), decreased appetite (26.6%), rash (20.9%), pyrexia (20.8%), diarrhea (20.6%), abdominal pain (20.2%), vomiting (19.2%), blood creatine increased (18.5%), thrombocytopenia (17.2%), pruritus (15.1%), hypothyroidism (12.6%), neuropathy peripheral (12.5%), leukopenia (10.9%), and aspartate aminotransferase increased (10.4%).1 'Health Canada's approval of this durvalumab-based perioperative regimen represents a major advance for Canadians with muscle invasive bladder cancer, where nearly half will relapse despite curative treatment,' says Dr. Srikala Sridhar, Professor of Medicine at the University of Toronto, Genitourinary Medical Oncologist at the Princess Margaret Cancer Centre and NIAGARA trial investigator. 'Findings from the NIAGARA trial showed that this new regimen reduces risk of recurrence and significantly improves survival – which may offer new hope and potential to transform care in this setting.' 'The high rate of recurrence associated with muscle invasive bladder cancer is an ongoing challenge and source of concern for physicians and patients,' says Dr. Normand Blais, Medical Oncologist at the Centre hospitalier de l'Université de Montréal. 'The Health Canada approval based on results from the NIAGARA trial may now offer us the opportunity to increase the chance of better patient outcomes and long-term survival by the use of immunotherapy in this setting, which is very good news for patients and their families.' Bladder cancer is the 5th most common cancer in Canada, with more than 13,000 patients diagnosed each year.3 The most common type of bladder cancer is urothelial carcinoma, which begins in the urothelial cells of the urinary tract. Bladder cancer is considered muscle invasive when there is evidence of the tumour invading the muscle wall of the bladder but no distant metastases.4 In MIBC, approximately 50% of patients who undergo bladder removal surgery experience disease recurrence.5 Treatment options that prevent disease recurrence after surgery are critically needed in this curative-intent setting. 'This decision by Health Canada represents an important step forward for all Canadians affected by muscle invasive bladder cancer,' says Michelle Colero, Executive Director, Bladder Cancer Canada. 'For many patients and families, the fear of recurrence after surgery has been overwhelming. This new treatment option may offer renewed hope for longer, healthier lives.' About NIAGARA2 NIAGARA is a randomized, open-label, multi-centre, global Phase III trial evaluating perioperative Imfinzi as treatment for patients with MIBC before and after radical cystectomy. In the trial, 1,063 patients were randomized to receive four cycles of Imfinzi plus neoadjuvant chemotherapy prior to cystectomy followed by eight cycles of Imfinzi monotherapy, or neoadjuvant chemotherapy alone prior to cystectomy with no further treatment after surgery. NIAGARA is the largest global Phase III trial in this setting to date. The trial is being conducted at 192 centres in 22 countries across North America (including Canada), South America, Europe, Australia and Asia. Its dual primary endpoints are EFS and pathologic complete response at the time of cystectomy. Key secondary endpoints are OS and safety. About Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. The company's core areas of scientific focus are Oncology; Cardiovascular, Renal and Metabolic (CVRM); Rare Disease; Respiratory & Immunology; and Vaccine & Immune Therapies. In Canada, the company employs more than 2,400 people and recently announced a major expansion of its research footprint in Mississauga – including the expansion of its AstraZeneca R&D Hub and the creation of a new Alexion Development Hub for Rare Diseases. AstraZeneca was recently recognized as one of Canada's Top 100 Employers, one of Canada's Most Admired Corporate Cultures, and a Greater Toronto Top Employer. AstraZeneca is committed to contributing to a more sustainable future for people, society and planet taking important steps to help tackle some of the most pressing sustainability challenges globally – from climate and biodiversity loss, to health equity and health system resilience. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. For more information, please visit the company's website at Imfinzi® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc. References: SOURCE AstraZeneca Canada Inc.
Yahoo
22-07-2025
- Business
- Yahoo
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MISSISSAUGA, Ontario, July 22, 2025--(BUSINESS WIRE)--MedX Health Corp. ("MedX" or the "Company") (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company's Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom's largest provider of occupational health services, where he led the company's technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX's UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality's direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world's largest wellness platform. As MedX's CEO, Gevisser will focus on expanding MedX's international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities. "John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX's operations," said Mike Druhan, MedX President, Dermatology Services. "His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success." "Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism," said John Gevisser. "As a former client, I saw firsthand how seamlessly MedX's hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance." While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. "The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time," said Ken McKay, Chairman of the Board.
National Post
17-07-2025
- Business
- National Post
Ryan Named One of the Best Workplaces™ for Inclusion in Canada for the Fourth Time
MISSISSAUGA, Ontario — Ryan, a leading global tax services and software provider, has been named to the list of Best Workplaces™ for Inclusion in Canada by Great Place To Work® for the fourth time in six years. THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors 'Being named to this prestigious list is a true testament to our unwavering commitment to fostering an inclusive and supportive workplace,' said Garry Round, Ryan President of Canadian Operations. 'I am incredibly proud of our team for their dedication to creating an environment where everyone feels valued, respected, and empowered to thrive.' The Best Workplaces for Inclusion in Canada list is based on direct feedback from the employees of the hundreds of organizations surveyed by Great Place To Work. To be eligible for this list, organizations must be Great Place To Work-Certified™ in the past year, and at least 90% of employees must agree they are treated fairly, regardless of personal characteristics such as gender, ethnicity, age, or sexual orientation. Companies who received the top employee responses to inclusion-related Trust Index statements were named to this year's list. Ryan leads the way in building an environment rooted in trust and belonging. This commitment is evident in initiatives such as RyanTHRIVE, which supports each team member's holistic well-being, and myRyan, a flexible work program that promotes work-life harmony. For information about exciting career opportunities at Ryan, visit the careers page of our Great Place To Work® Great Place To Work is the global authority on high-trust, high-performance workplace cultures. A global research and consulting firm, Great Place To Work provides the benchmarks and expertise needed to create, sustain, and recognize outstanding workplace cultures. In Canada, Great Place To Work produces both industry- and demographic-specific Best Workplace™ lists and represents the voices of 500,000 employees across industry. This is part of the largest annual workplace study, recognizing the world's Best Workplaces in a series of national lists, including those published by The Globe & Mail (Canada) and Fortune magazine (USA). Visit Great Place To Work at Ryan, an award-winning global tax services and software provider, is the largest Firm in the world dedicated exclusively to business taxes. The Firm provides an integrated suite of federal, provincial, and international tax services on a multijurisdictional basis, including tax recovery, consulting, advocacy, compliance, and technology services. Ryan is an 11-time recipient of the International Service Excellence Award from the Customer Service Institute of America (CSIA) for its commitment to world-class client service. Empowered by the dynamic myRyan work environment, which is widely recognized as the most innovative in the tax services industry, Ryan's multidisciplinary team of more than 5,900 professionals and associates serves over 77,000 clients in more than 80 countries, including many of the world's most prominent Global 5000 companies. More information about Ryan can be found at View source version on Director, Content and Communications Marketing
Globe and Mail
15-07-2025
- Business
- Globe and Mail
Chartwell Announces July 2025 Distribution and Provides Occupancy Update
MISSISSAUGA, ON , July 15, 2025 /CNW/ - Chartwell Retirement Residences ("Chartwell") (TSX: announced today a cash distribution of $0.051 per Trust Unit. The cash distribution will be payable on August 15, 2025 to unitholders of record on July 31, 2025 . Unitholders can participate in Chartwell's Distribution Reinvestment Plan ("DRIP"). Eligible investors registered in the DRIP will have their monthly cash distributions used to purchase Trust Units and will also receive bonus units equal to 3% of their monthly cash distributions. DRIP offers unitholders the opportunity to steadily increase their ownership in Chartwell without incurring any commission or brokerage fees. Complete details of the DRIP are available on Chartwell's website at or from a unitholder's investment advisor. Same Property Occupancy Update The chart included (Figure 1) summarizes Chartwell's same property monthly weighted average occupancy rates for the months ended December 31, 2023 , through to June 30, 2025 , and provides forecasts for same property weighted average occupancy for the months ending July 31, 2025 , and August 31 , 2025. We expect positive momentum in initial contacts, personalized tours and high conversion rates to permanent move-ins to continue through 2025, supported by strong demand resulting from accelerating demographic growth, shortages of long-term care beds, and fewer seniors housing construction starts. Forward-Looking Information This press release contains forward-looking information that reflects the current expectations, estimates and projections of management about the future results, performance, achievements, prospects or opportunities for Chartwell and the seniors housing industry. Forward-looking statements are based upon a number of assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond our control, and that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking statements. Examples of forward-looking information in this document include, but are not limited to, statements regarding our business strategies, including targets, and the expected results of such strategies, predictions and expectations with respect to industry trends regarding senior population growth, long term care bed shortages and the slowdown of new construction starts, and occupancy rate forecasts. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those expected or estimated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. These factors are more fully described in the "Risks and Uncertainties and Forward-Looking Information" section in our Management's Discussion and Analysis for the year ended December 31, 2024 (the "2024 MD&A"), and in materials filed with the securities regulatory authorities in Canada from time to time, including but not limited to our Annual Information Form (the "AIF"). A copy of the 2024 MD&A, the AIF and Chartwell's other publicly filed documents can be accessed under Chartwell's profile on SEDAR+ at Except as required by law, Chartwell does not intend to update or revise any forward-looking statements, whether as a result of new information, future events or for any other reason. ABOUT CHARTWELL Chartwell is in the business of serving and caring for Canada's seniors, committed to its vision of Making People's Lives BETTER and to providing a happier, healthier, and more fulfilling life experience for its residents. Chartwell is an unincorporated, open-ended real estate trust which indirectly owns and operates a complete range of seniors housing communities, from independent living through to assisted living and long-term care. Chartwell is one of the largest operators in Canada , serving approximately 25,000 residents in four provinces across the country. For more information, visit
Yahoo
10-07-2025
- Business
- Yahoo
goeasy Ltd. Recognized on TIME's List of Canada's Best Companies 2025
MISSISSAUGA, ON, July 10, 2025 /CNW/ - Today, goeasy Ltd. (TSX: GSY), one of Canada's leading consumer lenders focused on delivering a full suite of financial services to Canadians with near to non-prime credit, is pleased to announce that it has been recognized on TIME Magazine's inaugural list of Canada's Best Companies. This prestigious award was developed in partnership with Statista, a leading global provider of data and industry rankings. The full list was announced on July 10, 2025, and is available on "Being named one of Canada's Best Companies by TIME and Statista is a proud moment for goeasy and a reflection of the passion and purpose our team brings to work every day," said Dan Rees, Chief Executive Officer. "We've built a culture rooted in respect, performance, and opportunity—one where our employees feel empowered to grow, contribute meaningfully, and deliver exceptional experiences for our customers. This recognition is not just about where we are today, but about the bright future we're building together." TIME and Statista developed Canada's Best Companies list for 2025 by evaluating three key areas, including revenue growth, employee satisfaction and Environmental, Social and Governance (ESG) performance. The ranking included companies based in Canada with over $100 million in annual revenue. Revenue growth was analyzed using data from Statista's business databases to identify the fastest-growing companies. Employee satisfaction was assessed through three years of survey data from more than 49,000 workers. The evaluation also included Environmental, Social, and Governance (ESG) performance, measured using standardized indicators to produce an overall ESG score. About goeasy goeasy Ltd. is a Canadian company, headquartered in Mississauga, Ontario, that provides non-prime leasing and lending services through its easyhome, easyfinancial and LendCare brands. Supported by over 2,600 employees, the Company offers a wide variety of financial products and services including unsecured and secured instalment loans, merchant financing through a variety of verticals and lease-to-own merchandise. Customers can transact seamlessly through an omni-channel model that includes online and mobile platforms, over 400 locations across Canada, and point-of-sale financing offered in the retail, powersports, automotive, home improvement and healthcare verticals, through approximately 11,000 merchant partners across Canada. Throughout the Company's history, it has acquired and organically served over 1.5 million Canadians and originated over $16.6 billion in loans. Accredited by the Better Business Bureau, goeasy is the proud recipient of several awards in recognition of its exceptional culture and continued business growth including 2024 Best Workplaces™ in Financial Services & Insurance, Waterstone Canada's Most Admired Corporate Cultures, ranking on the 2022 Report on Business Women Lead Here executive gender diversity benchmark, placing on the 2024 Report on Business ranking of Canada's Top Growing Companies, ranking on the TSX30, Greater Toronto Top Employers Award and has been certified as a Great Place to Work®. The Company is represented by a diverse group of team members from over 90 nationalities who believe strongly in giving back to communities in which it operates. To date, goeasy has raised and donated over $6.5 million to support its long-standing partnerships with BGC Canada and many other local charities. goeasy Ltd.'s common shares are listed on the TSX under the trading symbol "GSY". goeasy is rated BB- with a stable trend from S&P and Ba3 with a stable trend from Moody's. For more information about goeasy and our business units, visit About Statista: Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of the leading data and business intelligence portal that provides statistics, business-relevant data, and various market and consumer studies and surveys. Media Contact: Dan ReesChief Executive Officer James ObrightSenior Vice President, Investor Relations & Capital Marketsinvestor_relations@ 905-272-2788 SOURCE goeasy Ltd View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
